Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.52 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.51 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 11/20 | 0.51 |
| ▸ | GAK | O14976 | 1/20 | 0.46 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.46 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.46 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.44 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23999449 | 1.00 | MAPKAPK2 (0.52) | MAPKAPK2PKN1PKN2KDRGAK | |
| SCHEMBL23999436 | 0.93 | KDR (0.59) | MAPKAPK2PKN1PKN2KDRGAK | |
| SCHEMBL23999350 | 0.93 | KDR (0.59) | MAPKAPK2PKN1PKN2KDRGAK | |
| SCHEMBL25826857 | 0.93 | KDR (0.58) | MAPKAPK2KDRGAKRIPK2COQ8A | |
| SCHEMBL23999877 | 0.89 | MAPKAPK2 (0.44) | MAPKAPK2PKN1PKN2KDRGAK | |
| SCHEMBL23999984 | 0.88 | MAPKAPK2 (0.51) | MAPKAPK2PKN1PKN2KDRGAK | |
| SCHEMBL24003905 | 0.86 | KDR (0.58) | MAPKAPK2PKN1PKN2KDRLRRK2 | |
| SCHEMBL23999408 | 0.86 | MAPKAPK2 (0.49) | MAPKAPK2PKN1PKN2KDRGAK | |
| SCHEMBL24006108 | 0.86 | KDR (0.58) | MAPKAPK2PKN1PKN2KDRLRRK2 | |
| SCHEMBL30180523 | 0.86 | MAPKAPK2 (0.49) | MAPKAPK2PKN1PKN2KDRGAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4426289-A1 | AKT3 MODULATORS | Georgiamune Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| EP-4426279-A1 | AKT3 MODULATORS | Georgiamune Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| CN-118574610-A | AKT3 modulators | 乔治穆内公司 | 2024-08-30 | — | — | CN | disclosed |
| CN-118524833-A | AKT3 modulators | 乔治穆内公司 | 2024-08-20 | — | — | CN | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
| WO-2023081854-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081845-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081845-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081854-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2023-05-11 | — | — | WO | disclosed |
| CN-115867266-A | AKT3 modulators | 乔治穆内有限责任公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-115867562-A | AKT3 modulators | 乔治穆内有限责任公司 | 2023-03-28 | — | — | CN | disclosed |
| EP-4146185-A1 | AKT3 MODULATORS | Georgiamune LLC (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-4146667-A1 | AKT3 MODULATORS | Georgiamune LLC (US) | 2023-03-15 | — | — | EP | disclosed |
| WO-2021226477-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021226519-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | MAPKAPK2 138/4885PKN1 781/4885PKN2 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.